Dyadic International (NASDAQ:DYAI) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Dyadic International Inc. (NASDAQ:DYAI) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.92 and traded as low as $0.8105. Dyadic International shares last traded at $0.8365, with a volume of 87,390 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Stock Performance

The company has a market cap of $30.48 million, a price-to-earnings ratio of -3.35 and a beta of 1.21. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.68 and a current ratio of 2.68. The company has a fifty day moving average of $0.82 and a two-hundred day moving average of $0.92.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $1.34 million. Dyadic International had a negative return on equity of 695.96% and a negative net margin of 239.67%. Equities research analysts anticipate that Dyadic International Inc. will post -0.12 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the last quarter. Perkins Capital Management Inc. grew its holdings in Dyadic International by 627.4% during the 3rd quarter. Perkins Capital Management Inc. now owns 348,050 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 300,200 shares during the last quarter. Truist Financial Corp increased its position in Dyadic International by 30.5% in the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after acquiring an additional 76,200 shares during the period. Landscape Capital Management L.L.C. acquired a new position in Dyadic International in the 3rd quarter valued at approximately $190,000. Finally, Marathon Capital Management bought a new position in shares of Dyadic International during the third quarter valued at $41,000. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.